Chronic Lymphocytic Leukemia Therapeutics Market, by Drug (Idelalisib (Zydelig), Venetoclax (Venclexta), Ibrutinib (Imbruvica), Ofatumumab (Arzerra), Fludarabine (Fludara), Obinutuzumab (Gazyva), Bendamustine Hydrochloride (Treanda), and Others) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East and Africa ) - Size, Share, Outlook, and Opportunity Analysis 2018- 2026

  • To Be Published : Oct 2019 |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Chronic lymphocytic leukemia (CLL) is a most common type of leukemia found in adults. It is a kind of malignancy characterized by production of abnormal white blood cells in the bone marrow. Symptoms include, swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Although CLL is rarely seen in children and people under age 40, it is more prevalent in geriatric population. Moreover, causes of CLL are largely unknown and it is more severe than acute leukemia. The prevalence of CLL is high in males than females. Although, the incidence of this disorder is higher in white population than Asian populations, the precise cause for this cannot be explained.

The diagnosis of CLL includes Blood Cell Count and Examination, Bone Marrow Examination for patients followed by treatment. The treatment includes single or combination drug therapy, targeted therapies, monoclonal antibody therapies, white blood cell (neutrophil) growth factors. In addition to this, there are radiation therapy and splenectomy which are rarely used for the treatment.

 Chronic Lymphocytic Leukemia Therapeutics Market - Drivers

High prevalence of CLL coupled with its high mortality rate, demonstrates the unmet market need for better therapeutics. According to the American Cancer Society (ACS) estimates, around 20,110 new cases of chronic lymphocytic leukemia and 4,660 deaths from CLL is expected in year 2017 in U.S. Furthermore, high prevalence of CLL in geriatric population is expected to increase demand for chronic lymphocytic leukemia therapeutics. According to the United Nations data, in 2015, around 901 million people in the world were over 60 years of age and this number is expected to reach 1.4 billion by 2030 and to 2.1 billion by 2050.

However, continuous research and development may contribute to the development of new treatments related to malignancies, including impaired immune system, genetic factors, and viruses. Thus expected to boost the market growth during the forecast period.

Furthermore, increasing number of incidences of comorbidities, especially among geriatric population and launch of new pipeline drugs are major factors contributing to growth of the chronic lymphocytic leukemia therapeutics market. For instance, on December 8, 2015, Bendeka injection—manufactured under the collaboration of Teva Pharmaceuticals Industries Ltd. and Eagle Pharmaceuticals Inc. acquired approval from FDA for the treatment of patients with CLL and indolent B-cell non-Hodgkin lymphoma (NHL) — progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

However, high costs and side effects associated with these drugs is expected to restrain growth of the market over the forecast period.

Chronic Lymphocytic Leukemia Therapeutics Market – Regional Analysis

On the basis of region, the chronic lymphocytic leukemia therapeutics market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America accounted for the largest market share in 2016 due to the presence of breakthrough pipeline drugs. For instance, the drug Acalabrutinib—manufactured by Acerta Pharma BV—is under phase 2 clinical trial for the treatment of CLL and small lymphocytic lymphoma (SLL) and the study is expected to complete in January 2019

 Increasing research activities along with increasing prevelance of CLL in US expected to propel the growth of CLL in North America. According to the Leukemia & Lymphoma Society, US, there are 119,386 patients in 2013 which has been increased to 15,720 in 2014.

Chronic Lymphocytic Leukemia Therapeutics Market – Competitor Analysis

Major players operating in the chronic lymphocytic leukemia therapeutics market include, F. Hoffmann-La Roche Ltd, Novartis International AG, GlaxoSmithKline Pharmaceuticals Limited, Celgene Corporation, Genmab A/S, Abbvie Inc. Teva Pharmaceutical Industries Ltd., Biogen Idec, AstraZeneca plc, Arno Therapeutics, Genzyme Corporation, Gilead Sciences INC., and others.

Chronic Lymphocytic Leukemia Therapeutics Market Taxonomy

By Drug

  • Bendamustine Hydrochloride (Treanda)
  • Prednisone
  • Idelalisib (Zydelig)
  • Venetoclax (Venclexta)
  • Ibrutinib (Imbruvica)
  • Ofatumumab (Arzerra)
  • Fludarabine (Fludara)
  • Obinutuzumab (Gazyva)
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.